BenevolentAI Investor Day Presentation Deck
Strategic validation: successful
collaboration with AstraZeneca
Multi-year Target-ID collaboration is
delivering multiple, novel targets for complex
diseases with high unmet need
Separate data environment established to integrate
AstraZeneca's data into a bespoke Knowledge Graph
BenevolentAl and AstraZeneca teams working in close
collaboration to explore, identify and validate targets
Deal structure of upfront license fee, milestone payments
and downstream royalties
Collaboration enables BenevolentAl to enrich its platform via
the data generated as part of the collaboration but also
further validate the use of our Al platform
AstraZeneca B
THERAPEUTIC AREAS
INITIAL DEAL (APRIL 2019)
Chronic kidney
disease (CKD)
GO
EXPANSION (DEC 2021)
Heart failure
KEY MILESTONES
CKD: Jan 2021
IPF: Dec 2021
do
To date, three novel targets have been validated
& selected for AstraZeneca's portfolio
IPF: May 2022
Idiopathic
pulmonary
fibrosis (IPF)
Systemic lupus
erythematosusView entire presentation